Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus

References

• Bootsma H Spronk P Derksen R Prevention of relapses in systemic lupus erythematosus Lancet 1995 345 8965 1595 1599 7783536
   PubMed Web of Science ®Google Scholar
• Tsokos GC Systemic lupus erythematosus N Engl J Med 2011 365 22 2110 2121 22129255
   PubMed Web of Science ®Google Scholar
• Rahman A Isenberg DA Systemic lupus erythematosus N Engl J Med 2008 358 9 929 939 18305268
   PubMed Web of Science ®Google Scholar
• Gatto M Zen M Ghirardello A Emerging and critical issues in the pathogenesis of lupus Autoimmun Rev 2013 12 4 523 536 23000207
   PubMed Web of Science ®Google Scholar
• Touma Z Gladman DD Tulloch-Reid D Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus Clin Exp Rheumatol 2010 28 4 525 531 20659409
   PubMed Web of Science ®Google Scholar
• Chan O Shlomchik MJ A new role for B-cells in systemic autoimmunity: B-cells promote spontaneous T cell activation in MRL-lpr/lpr mice J Immunol 1998 160 1 51 59 9551955
   PubMed Web of Science ®Google Scholar
• Harris DP Haynes L Sayles PC Reciprocal regulation of polarized cytokine production by effector B and T cells Nat Immunol 2000 1 6 475 482 11101868
   PubMed Web of Science ®Google Scholar
• Touma Z Urowitz MB Gladman DD Systemic lupus erythematosus: an update on current pharmacotherapy and future directions Expert Opin Biol Ther 2013 13 5 723 737 23339281
   PubMed Web of Science ®Google Scholar
• Ding HJ Gordon C New biologic therapy for systemic lupus erythematosus Curr Opin Pharmacol 2013 13 3 405 512 23664092
   PubMed Web of Science ®Google Scholar
• Rovin BH Furie R Latinis K Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study Arthritis Rheum 2012 64 4 1215 1226 22231479
   PubMed Web of Science ®Google Scholar
• Merrill JT Neuwelt CM Wallace DJ Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis Rheum 2010 62 1 222 233 20039413
   PubMed Web of Science ®Google Scholar
• Mysler EF Spindler AJ Guzman R Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study Arthritis Rheum 2013 65 9 2368 2379 23740801
   PubMed Web of Science ®Google Scholar
• Mok MY The immunological basis of B-cell therapy in systemic lupus erythematosus Int J Rheum Dis 2010 13 1 3 11 20374380
   PubMed Web of Science ®Google Scholar
• Traczewski P Rudnicka L Treatment of systemic lupus erythematosus with epratuzumab Br J Clin Pharmacol 2011 71 2 175 182 21219397
   PubMed Web of Science ®Google Scholar
• Leadbetter EA Rifkin IR Hohlbaum AM Beaudette BC Shlomchik MJ Marshak-Rothstein A Chromatin-IgG complexes activate B-cells by dual engagement of IgM and Toll-like receptors Nature 2002 416 6881 603 607 11948342
   PubMed Web of Science ®Google Scholar
• Fattah Z Isenberg DA Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies Expert Opin Biol Ther 2014 14 3 311 326 24387632
   PubMed Web of Science ®Google Scholar
• Nitschke L The role of CD22 and other inhibitory co-receptors in B-cell activation Curr Opin Immunol 2005 17 3 290 297 15886119
   PubMed Web of Science ®Google Scholar
• Looney RJ Anolik J Sanz I A perspective on B-cell-targeting therapy for SLE Mod Rheumatol 2010 20 1 1 10 19669389
   PubMed Web of Science ®Google Scholar
• Dorner T Jacobi AM Lipsky PE B-cells in autoimmunity Arthritis Res Ther 2009 11 5 247 19849820
   PubMed Web of Science ®Google Scholar
• Ding C Foote S Jones G B-cell-targeted therapy for systemic lupus erythematosus: an update BioDrugs 2008 22 4 239 249 18611066
   PubMed Web of Science ®Google Scholar
• Tedder TF Tuscano J Sato S Kehrl JH CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling Annu Rev Immunol 1997 15 481 504 9143697
   PubMed Web of Science ®Google Scholar
• Otipoby KL Andersson KB Draves KE CD22 regulates thymus-independent responses and the lifespan of B-cells Nature 1996 384 6610 634 637 8967951
   PubMed Web of Science ®Google Scholar
• Dorner T Kaufmann J Wegener WA Teoh N Goldenberg DM Burmester GR Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus Arthritis Res Ther 2006 8 3 R74 16630358
   PubMed Web of Science ®Google Scholar
• Wallace DJ Goldenberg DM Epratuzumab for systemic lupus erythematosus Lupus 2013 22 4 400 405 23553783
   PubMed Web of Science ®Google Scholar
• Goldenberg DM Epratuzumab in the therapy of oncological and immunological diseases Expert Rev Anticancer Ther 2006 6 10 1341 1353 17069520
   PubMed Web of Science ®Google Scholar
• Dorner T Goldenberg DM Targeting CD22 as a strategy for treating systemic autoimmune diseases Ther Clin Risk Manag 2007 3 5 953 959 18473018
   PubMedGoogle Scholar
• Edwards JC Cambridge G B-cell targeting in rheumatoid arthritis and other autoimmune diseases Nat Rev Immunol 2006 6 5 394 403 16622478
   PubMed Web of Science ®Google Scholar
• Rossi EA Goldenberg DM Michel R Rossi DL Wallace DJ Chang CH Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab Blood 2013 122 17 3020 3029 23821660
   PubMed Web of Science ®Google Scholar
• Jacobi AM Goldenberg DM Hiepe F Radbruch A Burmester GR Dorner T Differential effects of epratuzumab on peripheral blood B-cells of patients with systemic lupus erythematosus versus normal controls Ann Rheum Dis 2008 67 4 450 457 17673490
   PubMed Web of Science ®Google Scholar
• Carnahan J Wang P Kendall R Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clin Cancer Res 2003 9 10 Pt 2 3982S 3990S 14506197
   PubMed Web of Science ®Google Scholar
• Carnahan J Stein R Qu Z Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab Mol Immunol 2007 44 6 1331 1341 16814387
   PubMed Web of Science ®Google Scholar
• Beum PV Kennedy AD Williams ME Lindorfer MA Taylor RP The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes J Immunol 2006 176 4 2600 2609 16456022
   PubMed Web of Science ®Google Scholar
• Williams ME Densmore JJ Pawluczkowycz AW Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia J Immunol 2006 177 10 7435 7443 17082663
   PubMed Web of Science ®Google Scholar
• Wallace DJ Kalunian K Petri MA Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study Ann Rheum Dis 2014 73 1 183 190 23313811
   PubMed Web of Science ®Google Scholar
• Leonard JP Coleman M Ketas JC Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma J Clin Oncol 2003 21 16 3051 3059 12837807
   PubMed Web of Science ®Google Scholar
• Steinfeld SD Tant L Burmester GR Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study Arthritis Res Ther 2006 8 4 R129 16859536
   PubMed Web of Science ®Google Scholar
• Strand V Petri M Kalunian K Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006 Rheumatology (Oxford) 2014 53 3 502 511 24273022
   PubMed Web of Science ®Google Scholar
• Wallace DJ Gordon C Strand V Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up Rheumatology (Oxford) 2013 52 7 1313 1322 23542611
   PubMed Web of Science ®Google Scholar
• Petri M Hobbs K Gordon C Randomized controlled trials (RCTS) of epratuzumab (anti-CD22 MAB targeting B-cells) reveal clinically meaningful improvements in patients (pts) with moderate/severe SLE flares Ann Rheum Dis 2008 67 Suppl II 53
   Google Scholar
• Wallace D Hobbs K Houssiau F Randomized controlled trials of epratuzumab (anti-CD22 MAB targeting B-cells) reveal clinically meaningful reductions in corticosteroid use with favorable safety profile in moderate and severe flaring SLE patients Ann Rheum Dis 2008 67 Suppl II 212 17526555
   PubMed Web of Science ®Google Scholar
• Urowitz MB Gladman DD Tom BD Ibanez D Farewell VT Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus J Rheumatol 2008 35 11 2152 2158 18793004
   PubMed Web of Science ®Google Scholar
• Navarra SV Guzman RM Gallacher AE Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Lancet 2011 377 9767 721 731 21296403
   PubMed Web of Science ®Google Scholar
• Davies RJ Sangle SR Jordan NP Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis Lupus 2013 22 6 574 582 23632989
   PubMed Web of Science ®Google Scholar
• Lightstone L Minimising steroids in lupus nephritis – will B-cell depletion pave the way? Lupus 2013 22 4 390 399 23553782
   PubMed Web of Science ®Google Scholar
• Condon MB Ashby D Pepper RJ Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids Ann Rheum Dis 2013 72 8 1280 1286 23740227
   PubMed Web of Science ®Google Scholar
• Gunnarsson I Jonsdottir T Rituximab treatment in lupus nephritis – where do we stand? Lupus 2013 22 4 381 389 23553781
   PubMed Web of Science ®Google Scholar
• Moroni G Raffiotta F Trezzi B Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study Rheumatology (Oxford) 2014 53 9 1570 1577 24505125
   PubMed Web of Science ®Google Scholar
• Rovin BH Targeting B-cells in lupus nephritis: should cautions optimism remain? Nephrol Dial Transplant 2014 28 1 7 9 22844105
   PubMed Web of Science ®Google Scholar
• Touma Z Gladman DD Urowitz MB Clinical measures, metrics and indices Wallace DJ Hahn BH Dubois’ Lupus Erythematosus 8th ed Lippincott Williams and Wilkins Saunders 2012
   Google Scholar
• Strand V Gladman D Isenberg D Petri M Smolen J Tugwell P Outcome measures to be used in clinical trials in systemic lupus erythematosus J Rheumatol 1999 26 2 490 497 9972993
   PubMed Web of Science ®Google Scholar
• Touma Z Urowitz MB Gladman DD Outcome measures in systemic lupus erythematosus Indian Journal of Rheumatology 2013 8 Supp 1 S46 S53
   Google Scholar
• Bombardier C Gladman DD Urowitz MB Caron D Chang CH Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE Arthritis Rheum 1992 35 6 630 640 1599520
   PubMed Web of Science ®Google Scholar
• Symmons DP Coppock JS Bacon PA Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG) Q J Med 1988 69 259 927 937 3271336
   PubMedGoogle Scholar
• Isenberg DA Rahman A Allen E BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus Rheumatology (Oxford) 2005 44 7 902 906 15814577
   PubMed Web of Science ®Google Scholar
• Gladman DD Ibanez D Urowitz MB Systemic lupus erythematosus disease activity index 2000 J Rheumatol 2002 29 2 288 291 11838846
   PubMed Web of Science ®Google Scholar
• Touma Z Urowitz MB Ibanez D Gladman DD SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation Lupus 2011 20 1 67 70 21233149
   PubMed Web of Science ®Google Scholar
• Touma Z Gladman DD Ibanez D Urowitz MB Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50 J Rheumatol 2011 38 2 275 284 21123323
   PubMed Web of Science ®Google Scholar
• Touma Z Urowitz MB Taghavi-Zadeh S Ibanez D Gladman DD Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months Rheumatology (Oxford) 2012 51 10 1814 1819 22718868
   PubMed Web of Science ®Google Scholar
• Touma Z Gladman DD Ibanez D Urowitz MB SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years Lupus 2012 21 12 1305 1311 22800940
   PubMed Web of Science ®Google Scholar
• Furie RA Petri MA Wallace DJ Novel evidence-based systemic lupus erythematosus responder index Arthritis Rheum 2009 61 9 1143 1151 19714615
   PubMed Web of Science ®Google Scholar
• Thanou A Chakravarty E James JA Merrill J Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Science and Medicine 2014 1 1 e000005 25396057
   PubMedGoogle Scholar
• Petri M Pike MC Kelley L Kilgallen B Gordon C Systemic Lupus Erythematosus Responder Index Assessment of Responders in EMBLEM, a Phase IIb Study in Patients with Moderate to Severe Systemic Lupus Erythematosus Arthritis and Rheumatism 2011 63 Suppl 10 1378
   Google Scholar
• Sridharan ST Zhou T Immermann F Lehmann M Masferrer JL Honczarenko M Low placebo responses and clinical components of the biomarkers of lupus disease (BOLD) study may provide useful insights for SLE clinical trial design Arthritis Rheumatol 2011 63 Suppl S543
   Google Scholar
• Pike MC Kelley L Data quality challenges in systemic lupus erythematosus trials: how can this be optimized? Curr Rheumatol Rep 2012 14 4 324 333 22580894
   PubMed Web of Science ®Google Scholar